The 2-Minute Rule for Is ABBV-744 effective for hematologic cancers?
In Phase C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Members will receive treatment until eventually disorder progression or even the members are unable to tolerate the study drugs.There might be increased treatment burden for members Within this trial in comparison to thei